View ValuationGetinge 将来の成長Future 基準チェック /16Getinge利益と収益がそれぞれ年間11.8%と4.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に10.5% 11.8%なると予測されています。主要情報11.8%収益成長率11.79%EPS成長率Medical Equipment 収益成長16.1%収益成長率4.4%将来の株主資本利益率10.53%アナリストカバレッジGood最終更新日27 Apr 2026今後の成長に関する最新情報お知らせ • Oct 21Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency.お知らせ • Jan 28Getinge AB (publ) Provides Organic Sales Guidance for the Year 2025Getinge AB (publ) provided organic sales guidance for the year 2025. The company have a positive outlook on 2025 and expect organic sales growth of 2%-5% for the full year 2025.お知らせ • Feb 01+ 1 more updateGetinge AB (Publ) Provides Sales Guidance for the Year 2024Getinge AB (publ) provided sales guidance for the year 2024. Net sales for 2024 are expected to increase by 25% organically.お知らせ • Feb 03Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023Getinge provided financial guidance for the first half, second half and full year of 2023. For 2023 the company expecting a weaker first half of the year as a result of continuing challenging comparative figures for significant parts of Acute Care Therapies and Life Science.Whereas the second half of the year is expected to be stronger. This will result in healthy growth for the company in the second half of the year.Anticipated organic sales growth of 2-5% for the full-year.お知らせ • Oct 18Getinge AB Provides No Guidance for the Fourth Quarter of 2020 and for Year 2021Getinge AB provided no guidance for the fourth quarter of 2020 and for year 2021, because it all hinges on the -- both, of course, the -- say, how company handle the second wave of COVID-19, but also then the comeback of elective surgeries.お知らせ • Oct 16Getinge Not to Present Outlook for the Full Year 2020Due to the continuing uncertainty caused by the COVID-19 pandemic, Getinge has decided not to present outlook for the expected increase in the net sales for the full year 2020.すべての更新を表示Recent updatesお知らせ • Apr 22+ 1 more updateGetinge AB (publ) Approves Dividend, Payable from April 28, 2026Getinge AB (publ) approved the Dividend payment at its Annual General Meeting held on April 21, 2026. In accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.75 per share. April 23, 2026 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting April 28, 2026.お知らせ • Apr 10Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited.Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited on April 8, 2026. The acquisition strengthens Getinge’s offering to endoscopy units across the United Kingdom (UK) by combining Pennamed’s established consumables portfolio and strong customer relationships with Getinge’s expertise in endoscope reprocessing, infection control, and washer-disinfector technology. Getinge and Pennamed has combined 350 employees. Abi Godfrey, Alex Parry and Matt Harvey of Grant Thornton UK LLP acted as accountants for Pennamed Limited. Emma Orriss and Nigel Beckwith of Gosschalks LLP acted as legal advisors for Pennamed Limited. Covington & Burling Llp acted as legal advisor and Ernst & Young AB acted as accountant for Getinge AB. Getinge AB (publ) (OM:GETI B) completed the acquisition of Pennamed Limited on April 8, 2026.お知らせ • Mar 26+ 3 more updatesGetinge AB (publ) to Report Q2, 2026 Results on Jul 17, 2026Getinge AB (publ) announced that they will report Q2, 2026 results on Jul 17, 2026お知らせ • Mar 12Getinge AB (publ) Announces Malin Persson Declines Re-Election as Board Member, Effective April 21, 2026Getinge AB (publ) at its Annual General Meeting to be held on April 21, 2026, announced Malin Persson has declined re-election as board member.お知らせ • Jan 28Getinge AB (publ), Annual General Meeting, Apr 21, 2026Getinge AB (publ), Annual General Meeting, Apr 21, 2026.お知らせ • Jan 27Getinge AB (Publ) Proposes DividendGetinge AB (publ) announced the proposal of dividend per share of SEK 4.75 (4.60).お知らせ • Dec 19Getinge AB Announces Malin Persson Declines Re-Election to the BoardGetinge AB announced that Malin Persson, a board member since 2014, has announced that she will not be available for re-election to the board in 2026.お知らせ • Oct 21Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency.お知らせ • Jul 02Getinge AB (publ)(OM:GETI B) dropped from OMX Stockholm 30 IndexGetinge AB (publ) has been dropped from the OMX OMX Stockholm 30 Indexお知らせ • Apr 23+ 1 more updateGetinge AB (publ) Approves Dividend, Payable on April 29, 2025Getinge AB (publ) at its AGM held on April 22, 2025 approved dividend of SEK 4.60 per share. April 24, 2025 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting Tuesday April 29, 2025.お知らせ • Mar 28+ 1 more updateGetinge AB (publ) to Report Q3, 2025 Results on Oct 21, 2025Getinge AB (publ) announced that they will report Q3, 2025 results on Oct 21, 2025お知らせ • Mar 18Getinge Introduces Neural Pressure Support for the Servo-U Ventilator SystemGetinge announces the launch of its latest innovation in ICU ventilation – Neural Pressure Support (NPS) – available for both invasive and non-invasive ventilation. Building on its most personalized ventilation modes, NAVA and NIV NAVA, these two new NPS modes offer clinicians more options to provide personalized ventilation that aims to protect both the lungs and diaphragm. For years, Getinge has been market-driving when it comes to developing first-of-its-kind intensive care ventilation modes. The medtech company is introducing NPS and NIV NPS to widen its neurally controlled ventilation offering. The new Neural Pressure Support modes give clinicians the opportunity to deliver classical pressure support ventilation, enhanced with neural trigger and breath termination in synchrony with diaphragmatic muscle activity. This may be particularly beneficial for complex and challenging ICU patient groups, such as obstructive COPD patients requiring instant synchronization and fast pressurization, and restrictive ARDS patients with stiff lungs and an excessive respiratory drive.お知らせ • Jan 29Getinge AB (publ), Annual General Meeting, Apr 22, 2025Getinge AB (publ), Annual General Meeting, Apr 22, 2025. Location: halmstad Swedenお知らせ • Jan 28Getinge AB (publ) Provides Organic Sales Guidance for the Year 2025Getinge AB (publ) provided organic sales guidance for the year 2025. The company have a positive outlook on 2025 and expect organic sales growth of 2%-5% for the full year 2025.お知らせ • Dec 10+ 1 more updateGetinge AB (publ) to Report Q1, 2025 Results on Apr 22, 2025Getinge AB (publ) announced that they will report Q1, 2025 results on Apr 22, 2025お知らせ • Nov 28Getinge AB (Publ) Announces Changes of the Nomination CommitteeGetinge AB (publ) announced that the composition of Getinge AB (publ)'s Nomination Committee ahead of the 2025 Annual General Meeting has been updated following changed ownership structure in the company. As a consequence, Carnegie Fonder has appointed Simon Blecher as member of the Nomination Committee. This means that Getinge's Nomination Committee ahead of the 2025 Annual General Meeting comprises the company's Chairman, Johan Malmquist, and representatives from the following owners, listed by size: 1. Carl Bennet AB: Carl Bennet 2. Fourth Swedish National Pension Fund: Jannis Kitsakis 3. AMF Pension & Fonder: Dick Bergquist 4. Carnegie Fonder: Simon Blecher 5. Swedbank Robur: Marianne Nilsson.お知らせ • Nov 09Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024Getinge appointed Alexandra Holland as the new Executive Vice President of Communications effective November 11, 2024. Alexandra will become a member of the Getinge Executive Team and lead the development, advancement, and execution of the company's communications and public affairs strategy. Alexandra has dedicated her career to healthcare, including almost 15 years at Johnson & Johnson in the consumer, corporate, and medtech sectors. Most recently, Alexandra served as Vice President, Business and Culture Communications, MedTech, responsible for championing key initiatives to improve and protect reputation, drive business results, advance culture, and deliver value to patients, customers and shareholders. Alexandra Holland will report to Mattias Perjos and be a member of Getinge's executive team. She will be based in the United States and will take office on November 11th.お知らせ • Sep 13Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge. The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024. Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix. Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners on September 11, 2024. All conditions for the transaction have now been fulfilled.お知らせ • Aug 23Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge. The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024. Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix.お知らせ • Jul 01Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024Getinge AB (publ) announced that they will report Q2, 2024 results at 8:00 AM, Central European Standard Time on Jul 18, 2024お知らせ • Apr 23Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024Getinge AB (publ)'s Annual General Meeting held on 22 April 2024, approved in accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.40 per share. 24 April 2024 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting 29 April 2024.お知らせ • Mar 28+ 2 more updatesGetinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025Getinge AB (publ) announced that they will report fiscal year 2024 results on Jan 28, 2025お知らせ • Mar 16+ 1 more updateGetinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024Getinge AB (publ) announced that they will report fiscal year 2023 final results on Mar 27, 2024お知らせ • Mar 15+ 1 more updateGetinge AB (Publ) Proposes Dividend, Payable on April 29, 2024Getinge AB (publ) at its Annual General Meeting to be held on April 22, 2024, board and the CEO have proposed that a dividend of SEK 4.40 per share shall be declared. As record date for the dividend, the Board proposes April 24, 2024. If the AGM resolves in accordance with the proposal, the dividend is expected to be distributed by Euroclear Sweden AB starting April 29, 2024.お知らせ • Mar 08Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3Getinge announced the U.S. Food and Drug Administration's (FDA) 510(k) clearance of the Vasoview Hemopro 3, the latest addition to the medtech company's endoscopic vessel harvesting (EVH) solutions. Designed with customer centricity top of mind, the newcomer is expected to offer enhanced procedural efficiency in healthcare from the upcoming launch. Receiving the FDA 510(k) clearance for Vasoview Hemopro 3 marks a significant milestone for Getinge and underscores the effort to comply with the highest safety and effectiveness standards, emphasizing the medtech company's commitment to advancing medtech. The culmination of extensive market research and advisory boards conducted in partnership with clinicians within the EVH field, Vasoview Hemopro 3 represents collaborative innovation. Feedback from the studies has been central in shaping the product, focusing on improvements that enhance harvester efficiency and patient outcomes. Advancements include enhanced smoke evacuation, regulated energy control, ergonomic game controller style handle, and an integrated cable.お知らせ • Feb 01+ 1 more updateGetinge AB (Publ) Provides Sales Guidance for the Year 2024Getinge AB (publ) provided sales guidance for the year 2024. Net sales for 2024 are expected to increase by 25% organically.お知らせ • Jan 23Getinge Announces CFO ChangesLars Sandström is leaving the position as Getinge's CFO for a new opportunity outside of the company. He will be succeeded by Agneta Palmér, who has been working at Getinge since 2018, most recently in the role of Executive Vice President Operational Services and member of the executive management team. Agneta Palmér most recently served as Executive Vice President Operational Services and prior to that she was Vice President Corporate Control at Getinge. She has previously held similar positions at AB Volvo. The change will take effect at the end of March, when Lars Sandström leaves Getinge.お知らせ • Oct 12Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million on October 11, 2023. The acquisition has been financed through cash on hand and existing credit facilities. The statutorily required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) has passed. The transaction is closed and is not subject to further regulatory approvals or waiting periods.Getinge AB (publ) (OM:GETI B) completed the acquisition of Healthmark Industries Company, Inc. on October 11, 2023.お知らせ • Sep 20Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023Getinge announced that Jeanette Hedén Carlsson has decided to resign after 6 years as Executive Vice President, Brand & Communication, and member of the Executive Team. The process to recruit a successor will start immediately. Jeanette Hedén Carlsson will continue in her current role until December 31, 2023.お知らせ • Jul 08Getinge Receives US FDA 510(K) Clearance for Servo-Air® LiteGetinge announced clearance from the US FDA for Servo-air®? Lite, a wall gas independent non-invasive mechanical ventilator. Servo-air®?lite is Getinge's turbine-driven ventilator for non-invasive ventilation. Like all Servo ventilators, it offers ICU-quality ventilation but is more geared towards spontaneously breathing patients in need of extra breathing support. With its powerful turbine and long-lasting battery backup power, it can also be operated independent of wall gas and is suitable for intrahospital transports. It features embedded workflows, support for High Flow therapy, CO2 monitoring option and tools to support escalation of therapy if needed to. The product is expected to be available for customers in the US from September 2023.お知らせ • Jun 01Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million on May 31, 2023. The consideration comprises of approximately $120 million in cash on closing, on a cash and debt free basis. In addition, a maximum earn out of approximately $170 million can be paid out in 2024 - 2026 if agreed net revenue performance milestones are achieved in 2023 - 2025. The acquisition will be financed through cash at hand and Getinge's net debt to EBITDA ratio is expected to be impacted by 0.3x at the closing of deal. Getinge expects to have fully integrated HPNE by the end of 2024 and anticipates no material integration costs in 2023 - 2024. The acquisition is not expected to have a material impact on Getinge's operating profit and earnings per share in 2023. The transaction is subject to and conditional upon customary consents, closing and regulatory conditions being fulfilled, including review by the Committee on Foreign Investment in the United States and completion of the statutorily required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is expected to close in Q3 2023.お知らせ • Feb 03Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023Getinge provided financial guidance for the first half, second half and full year of 2023. For 2023 the company expecting a weaker first half of the year as a result of continuing challenging comparative figures for significant parts of Acute Care Therapies and Life Science.Whereas the second half of the year is expected to be stronger. This will result in healthy growth for the company in the second half of the year.Anticipated organic sales growth of 2-5% for the full-year.お知らせ • Feb 02Getinge AB (Publ) Proposes DividendGetinge AB (publ) proposed dividend per share of SEK 4.25 (SEK 4.00).お知らせ • Jan 30Getinge AB to Report Q4, 2022 Results on Feb 01, 2023Getinge AB announced that they will report Q4, 2022 results on Feb 01, 2023お知らせ • Feb 05Getinge AB Proposes Executive ChangesGetinge’s Nomination Committee proposes that Kristian Samuelsson, Professor of orthopaedic surgery at the University of Gothenburg and senior consultant in orthopaedic surgery at Sahlgrenska University Hospital, is elected new member of the Board at the Annual General Meeting on April 20, 2021. Kristian Samuelsson is proposed to succeed Johan Stern, who has declined re-election.お知らせ • Nov 11Getinge Is Announcing A Recall of HLS Set Advanced ProductsGetinge is announcing a global medical device recall for the HLS Set Advanced products due to a potential breach in sterile packaging. To date, there are no known adverse events associated with illness or injuries related to the mentioned products. Getinge has reported to relevant authorities according to applicable regulations and the cost for the recall is not material. The HLS Set Advanced is used for extracorporeal respiratory and/or cardiovascular support. Getinge has identified that a limited number of HLS Set Advanced products delivered worldwide beginning October 2018 could have a damaged sterile packaging. The affected products have a shelf life of 2 years and Getinge cannot estimate how many products remain with impacted customers. The cost for the recall is not material. All affected customers will or have received communication from Getinge regarding this recall according to local requirements.お知らせ • Oct 18Getinge AB Provides No Guidance for the Fourth Quarter of 2020 and for Year 2021Getinge AB provided no guidance for the fourth quarter of 2020 and for year 2021, because it all hinges on the -- both, of course, the -- say, how company handle the second wave of COVID-19, but also then the comeback of elective surgeries.お知らせ • Oct 16Getinge Not to Present Outlook for the Full Year 2020Due to the continuing uncertainty caused by the COVID-19 pandemic, Getinge has decided not to present outlook for the expected increase in the net sales for the full year 2020.お知らせ • Oct 04Getinge Announces Ventilation Technology for Both Premature Babies and AdultsGetinge that is groundbreaking both for premature babies and adults. Born 12 weeks too early with a 50/50 chance at survival, Sabina Checketts has grown up to becoma neonatal doctor herself, usising new therapies and sophisticated technology to improve outcomes for premature babies. One such technique called NAVA, invented by Getinge, utilizes sensors to help babies on ventilators breathe more easily and naturallyand it's increasingly being used on adults. And a new randomized study shows that NAVA can significantly shorten the time on the ventilator. Thirty-three years after her early birth, Checketts now works as a neonatal doctor in London. The ventilator that helped Checketts survive was a far cry from what she sees now when she treats premature babies. As vulnerable premature babies fight to stay alive one of the most critical issues is something most people never think twice about - breathing. A pivotal advance in neonatal medicine - and one that has a major impact in adult critical care - has been the development of better ventilators. One ventilation technique that breathes with the patient is called Neurally Adjusted Ventilatory Assist, or NAVA, developed by Getinge, a global leader in intensive care technology for both infants and adults. Electrodes on the catheter sense contractions in the diaphragm, resulting in an almost instantaneous signal that the patient wants to breathe. Synchronously, the ventilator supplies air. And when the electrodes sense the end of diaphragmatic contractions, the ventilator allows exhalation. Adults on ventilators generally start with a functioning diaphragm, but it will quickly become weaker if a machine breathes for them for too long. Getinge Medical Director Miray Kärnekull says that advanced ventilator technologies like NAVA are used regularly in adult patients in Europe to keep patients' diaphragm muscles active. And in a very recent multicenter randomised controlled trial, results showed that patients with acute respiratory failure on NAVA spent significantly less time on the ventilator and experienced less extubation failure compared to conventional lung-protective mechanical ventilation.お知らせ • Oct 02Getinge AB to Report Q3, 2020 Results on Oct 16, 2020Getinge AB announced that they will report Q3, 2020 results at 8:00 AM, Central European Standard Time on Oct 16, 2020お知らせ • Sep 24Getinge Announces Voluntary Recall of the Servo-i Ventilator System's Nebulizer ConnectorGetinge is announcing a voluntary medical device recall for the Servo-i ventilator system due to a potentially shorter than specified nebulizer connector. This issue does not affect the functionality of the Servo-i ventilator system. To date, there have been no adverse events reported resulting in serious illness or injuries related to the mentioned component. Getinge has reported to relevant authorities according to applicable regulations and the cost for the recall is not material. Getinge has identified that 997 units have been manufactured that potentially could be affected by a shorter than specified nebulizer connector. This may result in difficulties in installing the Aeroneb® Nebulizer module to the Servo-i device. The module is an option on the Servo-i which is intended for administering drugs to patients requiring mechanical ventilation. This issue does not affect the functionality of the Servo-i ventilator system. The Servo-i ventilator is intended for ventilator support and can be used for Neonatal, Pediatric and Adult patients.お知らせ • Sep 17Getinge AB Appoints Anna Romberg as Executive Vice President Legal, Compliance & Governance and Member, with Effect from October 01, 2020Getinge AB appointed Anna Romberg as Executive Vice President Legal, Compliance & Governance and member of the Getinge Executive Team. She takes up the position on October 1st, 2020. Anna most recently worked as management consultant, supporting global companies with compliance matters. Prior to this, she held the position as Vice President Ethics and Compliance, Cargotec Oyj 2016 - 2019. She has also held several governance and compliance related roles at Telia Company AB. Anna is currently a PhD candidate within Corporate Governance and Compliance Management Systems at Åbo Akademi University and expects to finalize her degree during the year. She is also one of the founders of the Nordic Business Ethics Network. In her new role, Anna will be a member of the Getinge Executive Team and report to Mattias Perjos, President & CEO. She takes up the position on October 1st, 2020.業績と収益の成長予測OTCPK:GNGB.F - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202838,4343,7364,2825,849812/31/202736,7103,3133,5415,0261012/31/202635,0102,8103,4664,952103/31/202634,0922,3593,3164,585N/A12/31/202534,9692,2582,6353,949N/A9/30/202535,8542,0543,1374,434N/A6/30/202535,4981,4902,7044,030N/A3/31/202535,5661,4792,4843,798N/A12/31/202434,7591,6383,2684,577N/A9/30/202433,5911,6912,5663,862N/A6/30/202433,3282,5843,2794,593N/A3/31/202432,1992,2853,2634,633N/A12/31/202331,8272,4121,6042,957N/A9/30/202330,4232,2511,3202,654N/A6/30/202329,7562,1541,2522,519N/A3/31/202329,2512,5431,1052,293N/A12/31/202228,2922,4912,2313,367N/A9/30/202227,7812,7072,8353,916N/A6/30/202227,1462,6653,0854,135N/A3/31/202227,0622,8604,1885,173N/A12/31/202127,0492,9705,6306,560N/A9/30/202127,9003,2926,5857,533N/A6/30/202129,5713,9166,8937,811N/A3/31/202129,9553,6127,0217,988N/A12/31/202029,8193,2396,1547,199N/A9/30/202029,4783,0505,2186,336N/A6/30/202027,7381,8784,2395,437N/A3/31/202027,0441,4873,4614,690N/A12/31/201926,5591,222N/A3,832N/A9/30/201925,9511,030N/A2,836N/A6/30/201925,398-632N/A3,082N/A3/31/201924,852-654N/A2,592N/A12/31/201824,172-967N/A2,503N/A9/30/201823,653-727N/A2,899N/A6/30/201822,914847N/A2,371N/A3/31/201822,552676N/A2,193N/A12/31/201722,4951,096N/A2,763N/A9/30/201717,061596N/A3,466N/A6/30/201719,046390N/A3,599N/A3/31/201720,604701N/A3,839N/A12/31/201622,170698N/A3,671N/A9/30/201629,6501,203N/A3,372N/A6/30/201629,6461,462N/A3,369N/A3/31/201629,9001,410N/A3,504N/A12/31/201530,2351,390N/A3,458N/A9/30/201529,3031,429N/A3,366N/A6/30/201528,6031,622N/A3,386N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: GNGB.Fの予測収益成長率 (年間11.8% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: GNGB.Fの収益 ( 11.8% ) US市場 ( 16.8% ) よりも低い成長が予測されています。高成長収益: GNGB.Fの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: GNGB.Fの収益 ( 4.4% ) US市場 ( 11.6% ) よりも低い成長が予測されています。高い収益成長: GNGB.Fの収益 ( 4.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: GNGB.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 10.5 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 08:46終値2026/05/13 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Getinge AB (publ) 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24 アナリスト機関null nullABG Sundal CollierScott BardoBerenbergDelphine Le LouetBernstein21 その他のアナリストを表示
お知らせ • Oct 21Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency.
お知らせ • Jan 28Getinge AB (publ) Provides Organic Sales Guidance for the Year 2025Getinge AB (publ) provided organic sales guidance for the year 2025. The company have a positive outlook on 2025 and expect organic sales growth of 2%-5% for the full year 2025.
お知らせ • Feb 01+ 1 more updateGetinge AB (Publ) Provides Sales Guidance for the Year 2024Getinge AB (publ) provided sales guidance for the year 2024. Net sales for 2024 are expected to increase by 25% organically.
お知らせ • Feb 03Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023Getinge provided financial guidance for the first half, second half and full year of 2023. For 2023 the company expecting a weaker first half of the year as a result of continuing challenging comparative figures for significant parts of Acute Care Therapies and Life Science.Whereas the second half of the year is expected to be stronger. This will result in healthy growth for the company in the second half of the year.Anticipated organic sales growth of 2-5% for the full-year.
お知らせ • Oct 18Getinge AB Provides No Guidance for the Fourth Quarter of 2020 and for Year 2021Getinge AB provided no guidance for the fourth quarter of 2020 and for year 2021, because it all hinges on the -- both, of course, the -- say, how company handle the second wave of COVID-19, but also then the comeback of elective surgeries.
お知らせ • Oct 16Getinge Not to Present Outlook for the Full Year 2020Due to the continuing uncertainty caused by the COVID-19 pandemic, Getinge has decided not to present outlook for the expected increase in the net sales for the full year 2020.
お知らせ • Apr 22+ 1 more updateGetinge AB (publ) Approves Dividend, Payable from April 28, 2026Getinge AB (publ) approved the Dividend payment at its Annual General Meeting held on April 21, 2026. In accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.75 per share. April 23, 2026 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting April 28, 2026.
お知らせ • Apr 10Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited.Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited on April 8, 2026. The acquisition strengthens Getinge’s offering to endoscopy units across the United Kingdom (UK) by combining Pennamed’s established consumables portfolio and strong customer relationships with Getinge’s expertise in endoscope reprocessing, infection control, and washer-disinfector technology. Getinge and Pennamed has combined 350 employees. Abi Godfrey, Alex Parry and Matt Harvey of Grant Thornton UK LLP acted as accountants for Pennamed Limited. Emma Orriss and Nigel Beckwith of Gosschalks LLP acted as legal advisors for Pennamed Limited. Covington & Burling Llp acted as legal advisor and Ernst & Young AB acted as accountant for Getinge AB. Getinge AB (publ) (OM:GETI B) completed the acquisition of Pennamed Limited on April 8, 2026.
お知らせ • Mar 26+ 3 more updatesGetinge AB (publ) to Report Q2, 2026 Results on Jul 17, 2026Getinge AB (publ) announced that they will report Q2, 2026 results on Jul 17, 2026
お知らせ • Mar 12Getinge AB (publ) Announces Malin Persson Declines Re-Election as Board Member, Effective April 21, 2026Getinge AB (publ) at its Annual General Meeting to be held on April 21, 2026, announced Malin Persson has declined re-election as board member.
お知らせ • Jan 28Getinge AB (publ), Annual General Meeting, Apr 21, 2026Getinge AB (publ), Annual General Meeting, Apr 21, 2026.
お知らせ • Jan 27Getinge AB (Publ) Proposes DividendGetinge AB (publ) announced the proposal of dividend per share of SEK 4.75 (4.60).
お知らせ • Dec 19Getinge AB Announces Malin Persson Declines Re-Election to the BoardGetinge AB announced that Malin Persson, a board member since 2014, has announced that she will not be available for re-election to the board in 2026.
お知らせ • Oct 21Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency.
お知らせ • Jul 02Getinge AB (publ)(OM:GETI B) dropped from OMX Stockholm 30 IndexGetinge AB (publ) has been dropped from the OMX OMX Stockholm 30 Index
お知らせ • Apr 23+ 1 more updateGetinge AB (publ) Approves Dividend, Payable on April 29, 2025Getinge AB (publ) at its AGM held on April 22, 2025 approved dividend of SEK 4.60 per share. April 24, 2025 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting Tuesday April 29, 2025.
お知らせ • Mar 28+ 1 more updateGetinge AB (publ) to Report Q3, 2025 Results on Oct 21, 2025Getinge AB (publ) announced that they will report Q3, 2025 results on Oct 21, 2025
お知らせ • Mar 18Getinge Introduces Neural Pressure Support for the Servo-U Ventilator SystemGetinge announces the launch of its latest innovation in ICU ventilation – Neural Pressure Support (NPS) – available for both invasive and non-invasive ventilation. Building on its most personalized ventilation modes, NAVA and NIV NAVA, these two new NPS modes offer clinicians more options to provide personalized ventilation that aims to protect both the lungs and diaphragm. For years, Getinge has been market-driving when it comes to developing first-of-its-kind intensive care ventilation modes. The medtech company is introducing NPS and NIV NPS to widen its neurally controlled ventilation offering. The new Neural Pressure Support modes give clinicians the opportunity to deliver classical pressure support ventilation, enhanced with neural trigger and breath termination in synchrony with diaphragmatic muscle activity. This may be particularly beneficial for complex and challenging ICU patient groups, such as obstructive COPD patients requiring instant synchronization and fast pressurization, and restrictive ARDS patients with stiff lungs and an excessive respiratory drive.
お知らせ • Jan 29Getinge AB (publ), Annual General Meeting, Apr 22, 2025Getinge AB (publ), Annual General Meeting, Apr 22, 2025. Location: halmstad Sweden
お知らせ • Jan 28Getinge AB (publ) Provides Organic Sales Guidance for the Year 2025Getinge AB (publ) provided organic sales guidance for the year 2025. The company have a positive outlook on 2025 and expect organic sales growth of 2%-5% for the full year 2025.
お知らせ • Dec 10+ 1 more updateGetinge AB (publ) to Report Q1, 2025 Results on Apr 22, 2025Getinge AB (publ) announced that they will report Q1, 2025 results on Apr 22, 2025
お知らせ • Nov 28Getinge AB (Publ) Announces Changes of the Nomination CommitteeGetinge AB (publ) announced that the composition of Getinge AB (publ)'s Nomination Committee ahead of the 2025 Annual General Meeting has been updated following changed ownership structure in the company. As a consequence, Carnegie Fonder has appointed Simon Blecher as member of the Nomination Committee. This means that Getinge's Nomination Committee ahead of the 2025 Annual General Meeting comprises the company's Chairman, Johan Malmquist, and representatives from the following owners, listed by size: 1. Carl Bennet AB: Carl Bennet 2. Fourth Swedish National Pension Fund: Jannis Kitsakis 3. AMF Pension & Fonder: Dick Bergquist 4. Carnegie Fonder: Simon Blecher 5. Swedbank Robur: Marianne Nilsson.
お知らせ • Nov 09Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024Getinge appointed Alexandra Holland as the new Executive Vice President of Communications effective November 11, 2024. Alexandra will become a member of the Getinge Executive Team and lead the development, advancement, and execution of the company's communications and public affairs strategy. Alexandra has dedicated her career to healthcare, including almost 15 years at Johnson & Johnson in the consumer, corporate, and medtech sectors. Most recently, Alexandra served as Vice President, Business and Culture Communications, MedTech, responsible for championing key initiatives to improve and protect reputation, drive business results, advance culture, and deliver value to patients, customers and shareholders. Alexandra Holland will report to Mattias Perjos and be a member of Getinge's executive team. She will be based in the United States and will take office on November 11th.
お知らせ • Sep 13Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge. The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024. Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix. Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners on September 11, 2024. All conditions for the transaction have now been fulfilled.
お知らせ • Aug 23Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge. The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024. Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix.
お知らせ • Jul 01Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024Getinge AB (publ) announced that they will report Q2, 2024 results at 8:00 AM, Central European Standard Time on Jul 18, 2024
お知らせ • Apr 23Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024Getinge AB (publ)'s Annual General Meeting held on 22 April 2024, approved in accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.40 per share. 24 April 2024 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting 29 April 2024.
お知らせ • Mar 28+ 2 more updatesGetinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025Getinge AB (publ) announced that they will report fiscal year 2024 results on Jan 28, 2025
お知らせ • Mar 16+ 1 more updateGetinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024Getinge AB (publ) announced that they will report fiscal year 2023 final results on Mar 27, 2024
お知らせ • Mar 15+ 1 more updateGetinge AB (Publ) Proposes Dividend, Payable on April 29, 2024Getinge AB (publ) at its Annual General Meeting to be held on April 22, 2024, board and the CEO have proposed that a dividend of SEK 4.40 per share shall be declared. As record date for the dividend, the Board proposes April 24, 2024. If the AGM resolves in accordance with the proposal, the dividend is expected to be distributed by Euroclear Sweden AB starting April 29, 2024.
お知らせ • Mar 08Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3Getinge announced the U.S. Food and Drug Administration's (FDA) 510(k) clearance of the Vasoview Hemopro 3, the latest addition to the medtech company's endoscopic vessel harvesting (EVH) solutions. Designed with customer centricity top of mind, the newcomer is expected to offer enhanced procedural efficiency in healthcare from the upcoming launch. Receiving the FDA 510(k) clearance for Vasoview Hemopro 3 marks a significant milestone for Getinge and underscores the effort to comply with the highest safety and effectiveness standards, emphasizing the medtech company's commitment to advancing medtech. The culmination of extensive market research and advisory boards conducted in partnership with clinicians within the EVH field, Vasoview Hemopro 3 represents collaborative innovation. Feedback from the studies has been central in shaping the product, focusing on improvements that enhance harvester efficiency and patient outcomes. Advancements include enhanced smoke evacuation, regulated energy control, ergonomic game controller style handle, and an integrated cable.
お知らせ • Feb 01+ 1 more updateGetinge AB (Publ) Provides Sales Guidance for the Year 2024Getinge AB (publ) provided sales guidance for the year 2024. Net sales for 2024 are expected to increase by 25% organically.
お知らせ • Jan 23Getinge Announces CFO ChangesLars Sandström is leaving the position as Getinge's CFO for a new opportunity outside of the company. He will be succeeded by Agneta Palmér, who has been working at Getinge since 2018, most recently in the role of Executive Vice President Operational Services and member of the executive management team. Agneta Palmér most recently served as Executive Vice President Operational Services and prior to that she was Vice President Corporate Control at Getinge. She has previously held similar positions at AB Volvo. The change will take effect at the end of March, when Lars Sandström leaves Getinge.
お知らせ • Oct 12Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million on October 11, 2023. The acquisition has been financed through cash on hand and existing credit facilities. The statutorily required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) has passed. The transaction is closed and is not subject to further regulatory approvals or waiting periods.Getinge AB (publ) (OM:GETI B) completed the acquisition of Healthmark Industries Company, Inc. on October 11, 2023.
お知らせ • Sep 20Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023Getinge announced that Jeanette Hedén Carlsson has decided to resign after 6 years as Executive Vice President, Brand & Communication, and member of the Executive Team. The process to recruit a successor will start immediately. Jeanette Hedén Carlsson will continue in her current role until December 31, 2023.
お知らせ • Jul 08Getinge Receives US FDA 510(K) Clearance for Servo-Air® LiteGetinge announced clearance from the US FDA for Servo-air®? Lite, a wall gas independent non-invasive mechanical ventilator. Servo-air®?lite is Getinge's turbine-driven ventilator for non-invasive ventilation. Like all Servo ventilators, it offers ICU-quality ventilation but is more geared towards spontaneously breathing patients in need of extra breathing support. With its powerful turbine and long-lasting battery backup power, it can also be operated independent of wall gas and is suitable for intrahospital transports. It features embedded workflows, support for High Flow therapy, CO2 monitoring option and tools to support escalation of therapy if needed to. The product is expected to be available for customers in the US from September 2023.
お知らせ • Jun 01Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million on May 31, 2023. The consideration comprises of approximately $120 million in cash on closing, on a cash and debt free basis. In addition, a maximum earn out of approximately $170 million can be paid out in 2024 - 2026 if agreed net revenue performance milestones are achieved in 2023 - 2025. The acquisition will be financed through cash at hand and Getinge's net debt to EBITDA ratio is expected to be impacted by 0.3x at the closing of deal. Getinge expects to have fully integrated HPNE by the end of 2024 and anticipates no material integration costs in 2023 - 2024. The acquisition is not expected to have a material impact on Getinge's operating profit and earnings per share in 2023. The transaction is subject to and conditional upon customary consents, closing and regulatory conditions being fulfilled, including review by the Committee on Foreign Investment in the United States and completion of the statutorily required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is expected to close in Q3 2023.
お知らせ • Feb 03Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023Getinge provided financial guidance for the first half, second half and full year of 2023. For 2023 the company expecting a weaker first half of the year as a result of continuing challenging comparative figures for significant parts of Acute Care Therapies and Life Science.Whereas the second half of the year is expected to be stronger. This will result in healthy growth for the company in the second half of the year.Anticipated organic sales growth of 2-5% for the full-year.
お知らせ • Feb 02Getinge AB (Publ) Proposes DividendGetinge AB (publ) proposed dividend per share of SEK 4.25 (SEK 4.00).
お知らせ • Jan 30Getinge AB to Report Q4, 2022 Results on Feb 01, 2023Getinge AB announced that they will report Q4, 2022 results on Feb 01, 2023
お知らせ • Feb 05Getinge AB Proposes Executive ChangesGetinge’s Nomination Committee proposes that Kristian Samuelsson, Professor of orthopaedic surgery at the University of Gothenburg and senior consultant in orthopaedic surgery at Sahlgrenska University Hospital, is elected new member of the Board at the Annual General Meeting on April 20, 2021. Kristian Samuelsson is proposed to succeed Johan Stern, who has declined re-election.
お知らせ • Nov 11Getinge Is Announcing A Recall of HLS Set Advanced ProductsGetinge is announcing a global medical device recall for the HLS Set Advanced products due to a potential breach in sterile packaging. To date, there are no known adverse events associated with illness or injuries related to the mentioned products. Getinge has reported to relevant authorities according to applicable regulations and the cost for the recall is not material. The HLS Set Advanced is used for extracorporeal respiratory and/or cardiovascular support. Getinge has identified that a limited number of HLS Set Advanced products delivered worldwide beginning October 2018 could have a damaged sterile packaging. The affected products have a shelf life of 2 years and Getinge cannot estimate how many products remain with impacted customers. The cost for the recall is not material. All affected customers will or have received communication from Getinge regarding this recall according to local requirements.
お知らせ • Oct 18Getinge AB Provides No Guidance for the Fourth Quarter of 2020 and for Year 2021Getinge AB provided no guidance for the fourth quarter of 2020 and for year 2021, because it all hinges on the -- both, of course, the -- say, how company handle the second wave of COVID-19, but also then the comeback of elective surgeries.
お知らせ • Oct 16Getinge Not to Present Outlook for the Full Year 2020Due to the continuing uncertainty caused by the COVID-19 pandemic, Getinge has decided not to present outlook for the expected increase in the net sales for the full year 2020.
お知らせ • Oct 04Getinge Announces Ventilation Technology for Both Premature Babies and AdultsGetinge that is groundbreaking both for premature babies and adults. Born 12 weeks too early with a 50/50 chance at survival, Sabina Checketts has grown up to becoma neonatal doctor herself, usising new therapies and sophisticated technology to improve outcomes for premature babies. One such technique called NAVA, invented by Getinge, utilizes sensors to help babies on ventilators breathe more easily and naturallyand it's increasingly being used on adults. And a new randomized study shows that NAVA can significantly shorten the time on the ventilator. Thirty-three years after her early birth, Checketts now works as a neonatal doctor in London. The ventilator that helped Checketts survive was a far cry from what she sees now when she treats premature babies. As vulnerable premature babies fight to stay alive one of the most critical issues is something most people never think twice about - breathing. A pivotal advance in neonatal medicine - and one that has a major impact in adult critical care - has been the development of better ventilators. One ventilation technique that breathes with the patient is called Neurally Adjusted Ventilatory Assist, or NAVA, developed by Getinge, a global leader in intensive care technology for both infants and adults. Electrodes on the catheter sense contractions in the diaphragm, resulting in an almost instantaneous signal that the patient wants to breathe. Synchronously, the ventilator supplies air. And when the electrodes sense the end of diaphragmatic contractions, the ventilator allows exhalation. Adults on ventilators generally start with a functioning diaphragm, but it will quickly become weaker if a machine breathes for them for too long. Getinge Medical Director Miray Kärnekull says that advanced ventilator technologies like NAVA are used regularly in adult patients in Europe to keep patients' diaphragm muscles active. And in a very recent multicenter randomised controlled trial, results showed that patients with acute respiratory failure on NAVA spent significantly less time on the ventilator and experienced less extubation failure compared to conventional lung-protective mechanical ventilation.
お知らせ • Oct 02Getinge AB to Report Q3, 2020 Results on Oct 16, 2020Getinge AB announced that they will report Q3, 2020 results at 8:00 AM, Central European Standard Time on Oct 16, 2020
お知らせ • Sep 24Getinge Announces Voluntary Recall of the Servo-i Ventilator System's Nebulizer ConnectorGetinge is announcing a voluntary medical device recall for the Servo-i ventilator system due to a potentially shorter than specified nebulizer connector. This issue does not affect the functionality of the Servo-i ventilator system. To date, there have been no adverse events reported resulting in serious illness or injuries related to the mentioned component. Getinge has reported to relevant authorities according to applicable regulations and the cost for the recall is not material. Getinge has identified that 997 units have been manufactured that potentially could be affected by a shorter than specified nebulizer connector. This may result in difficulties in installing the Aeroneb® Nebulizer module to the Servo-i device. The module is an option on the Servo-i which is intended for administering drugs to patients requiring mechanical ventilation. This issue does not affect the functionality of the Servo-i ventilator system. The Servo-i ventilator is intended for ventilator support and can be used for Neonatal, Pediatric and Adult patients.
お知らせ • Sep 17Getinge AB Appoints Anna Romberg as Executive Vice President Legal, Compliance & Governance and Member, with Effect from October 01, 2020Getinge AB appointed Anna Romberg as Executive Vice President Legal, Compliance & Governance and member of the Getinge Executive Team. She takes up the position on October 1st, 2020. Anna most recently worked as management consultant, supporting global companies with compliance matters. Prior to this, she held the position as Vice President Ethics and Compliance, Cargotec Oyj 2016 - 2019. She has also held several governance and compliance related roles at Telia Company AB. Anna is currently a PhD candidate within Corporate Governance and Compliance Management Systems at Åbo Akademi University and expects to finalize her degree during the year. She is also one of the founders of the Nordic Business Ethics Network. In her new role, Anna will be a member of the Getinge Executive Team and report to Mattias Perjos, President & CEO. She takes up the position on October 1st, 2020.